DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for Duchenne muscular dystrophy — screening already-approved drugs against its 47-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleDuchenne muscular dystrophy maps to a 47-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for duchenne muscular dystrophy is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
nuclear receptor subfamily 3 group C member 2 (NR3C2) — NR3C2 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet 2,2-difluoro-3-hydroxypropyldrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 4PF3 · 1.1 Å · ligand 6-[1-(2,2-difluoro-3-hydroxypropyl)-5-(4-fluorophenyl)-3-methyl-1H-pyrazol-4-yl]-2H-1,4-benzoxazin-3(4H)-one (HFN). Experimental structure, not a prediction.
What the evidence adds up to
Duchenne muscular dystrophy is an X-linked recessive disorder affecting 1 in 3,500 males, caused by a mutation in the dystrophin gene on Xp21. In a 2008 observational study of eight patients, the average age at diagnosis was five years; six had delayed psychomotor development, seven had abnormal gait as the main presenting complaint along with frequent falls, and three had died by the end of the study period. The authors stated that multidisciplinary treatment is needed to slow progression while no curative treatment exists, and that early diagnosis requires knowledge of the disease’s key features.
A 1989 paper noted that despite the cloning of the dystrophin gene and the finding that dystrophin is absent in Duchenne muscular dystrophy, these molecular advances had not yet changed clinical management. The disease remained invariably fatal. A 2008 review described the availability of a recombinant dystrophin cDNA and animal models for gene therapy development, but reported only current progress toward such therapy, not clinical results.
A 2018 article addressed the need to evaluate how well the 2010 Care Considerations for Duchenne muscular dystrophy had been implemented, offering suggestions for assessing uptake of key care elements. A 2023 consensus statement identified the core standards of care as early diagnosis, prevention and treatment of osteoporosis, daily physical therapy, regular rehabilitation, glucocorticosteroids, and monitoring of heart and lung function. It stated that the clinical effect of new targeted pathogenetic therapies that restore synthesis of full or truncated dystrophin depends on their appropriate combination with these existing standards.
What is still missing is evidence from controlled trials that any gene therapy or other pathogenetic approach, when added to standard care, improves survival or function in a meaningful number of patients. The 2023 consensus explicitly conditions any clinical effect on proper combination with existing care, but does not provide data from such combination regimens. The small sample size and descriptive nature of the 2008 study, the lack of updated implementation data from the 2018 evaluation, and the absence of randomised trial results for any new therapy all limit what can be concluded.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Neurology · 2006 · 20 citations
Duchenne Muscular Dystrophy: Advances in Therapeutics
AbstractDuchenne Muscular Dystrophy: Advances in Therapeutics
edited by J.S. Chamberlain and T.A. Rando, 450 pp., Taylor and Francis Group, 2006
This timely book has an introduction by A.E.H Emery and is then divided into four sections with individual chapters being written by one or more experts in that field. One of the major strengths of the book is its simple, logical layout. Section I (“Duchenne Muscular Dystrophy Background”) encompasses a clinical overview of DMD, the role of dystrophin and the dystrophin-associated …
AbstractDespite recent advances in our understanding of the muscular dystrophies, current therapy for these disorders remains chiefly supportive. With the exception of prednisone for Duchenne dystrophy, no effective treatment for these disorders has been found that will improve strength or even slow the progression of weakness. This review highlights current strategies for treating muscular dystrophies and discusses recent trials of various pharmacologic agents, including corticosteroids, anabolic steroids, growth factors and beta-adrenergic agonists. The outlook for effective gene therapy is also presented.
Revista chilena de pediatría · 2008 · 12 citations · open access
Distrofia muscular de Duchenne, presentación clínica
AbstractIntroducción: La distrofia muscular de Duchenne es una alteración ligada al X recesiva que afecta 1 en 3 500 varones. La distrofia muscular de Becker es menos común, afectando aproximadamente 1 en 30 000 varones. Ambas resultan de la mutación de un gen localizado en Xp21, el cual codifica a la distrofina. Objetivos: Describir el comportamiento clínico de la distrofia muscular de Duchenne en pacientes evaluados en nuestra institución. Pacientes y Métodos: Se realizó un estudio de tipo observacional y descriptivo, donde se revisaron las historias clínicas de ocho pacientes con el diagnóstico de distrofia muscular de Duchenne, donde se describieron los aspectos clínicos y paraclínicos de la entidad. Resultados: El promedio de la edad para el momento del diagnóstico fue de cinco años. Seis presentaron retardo del desarrollo psicomotor y la marcha se encontró alterada en siete pacientes siendo este el principal motivo de consulta junto a caídas frecuentes. Tres pacientes habían fallecido al final del período en estudio. Conclusiones: Se requiere de un tratamiento multidisciplinario para retrasar la evolución de la enfermedad, mientras no se disponga de un tratamiento curativo. Es necesario conocer los aspectos representativos de esta enfermedad para realizar su diagnóstico precoz.
New England Journal of Medicine · 1989 · 12 citations
Prednisone Therapy for Duchenne's Muscular Dystrophy
AbstractIn the past five years, progress in understanding the molecular basis of Duchenne's muscular dystrophy has been substantial. The affected gene in this disease has been cloned, and its protein product, dystrophin, characterized.1 The importance of dystrophin in the pathogenesis of this disorder has been defined: dystrophin is absent from muscle in Duchenne's muscular dystrophy and is usually present but of abnormal size in Becker's muscular dystrophy, a milder variant.2 Unfortunately, these dramatic advances have not yet had an effect on the clinical management of muscular dystrophy. Duchenne's muscular dystrophy remains invariably fatal. The disease is common, occurring in approximately . . .
Gene Therapy Prospects for Duchenne Muscular Dystrophy
AbstractDuchenne muscular dystrophy (DMD) is a devastating neuromuscular disorder caused by mutations in the dystrophin gene. The lack of adequate therapy for this disease provides impetus for the development of gene therapy strategies. A recombinant dystrophin cDNA and animal models of the disease are available for this therapy development. Characterization of these reagents and current progress toward gene therapy for DMD will be described.
Evaluating Implementation of the Updated Care Considerations for Duchenne Muscular Dystrophy
AbstractCare Considerations for Duchenne Muscular Dystrophy were published in 2010. However, little is known about the extent to which these considerations were implemented after publication. With this article, we provide direction on evaluating the uptake of the 2018 Duchenne Muscular Dystrophy Care Considerations. We identify key elements of care and present suggestions for their use in evaluation and research.
Neuromuscular Diseases · 2023 · 4 citations · open access
Consensus concept of modern effective therapy for Duchenne muscular dystrophy
AbstractDuchenne muscular dystrophy is a genetic orphan neuromuscular disease caused by a mutation in the DMD gene encoding the protein dystrophin. As a result of developing and progressive muscle damage and atrophy, children lose the ability to walk, develop respiratory and cardiac disorders. The core elements of good care standards are early diagnosis, prevention and treatment of osteoporosis, daily physical therapy, regular rehabilitation, glucocorticosteroids, and control of heart and lung function. The clinical effect of new targeted pathogenetic therapies for Duchenne muscular dystrophy, restoring synthesis of full or truncated dystrophin, depend on their appropriate combination with existing standards of care.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
